[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 16, 1996

Consortium 'Gangs Up' on Prostate Cancer

JAMA. 1996;276(15):1209. doi:10.1001/jama.1996.03540150011004

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


CaP CURE'S LATEST APPROACH to finding a cure for prostate cancer is a consortium.

CaP CURE is the Association for Cure of Cancer of the Prostate (JAMA. 1996; 275:350).

It was founded 3 years ago by the controversial investment banker Michael Milken, who usually is identified with so-called junk bonds and with playing a key role in reshaping capital markets. He took this step shortly after learning at age 46 of his own prostate cancer, radiation and hormone treatment outcome for which is being monitored closely as he enters his 50s.

So far, Milken has raised approximately $25 million in addition to contributions from his personal fortune to vitalize prostate cancer research by investigators who are exploring a variety of therapeutic, genetic, molecular, prophylactic, and diagnostic approaches with a new urgency. Typical of Milken's innovative, feet-to-the-fire emphasis is the unique new (10 months old) genetics consortium whose members made their